Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

Lawrence A LeiterItamar RazStephen D WiviottMeir SchechterErica L GoodrichIlan YanuvAliza RozenbergSabina A MurphyThomas A ZelnikerAnna Maria LangkildeIngrid A M Gause-NilssonMartin FredrikssonPeter A JohanssonJohn P H WildingDarren K McGuireDeepak L BhattLawrence A LeiterAvivit CahnJamie P DwyerHiddo J L HeerspinkMarc S Sabatine

Published in: Diabetes care (2022)

Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.

Keyphrases

type diabetes
clinical trial
study protocol
phase iii
randomized controlled trial
phase ii
wound healing
open label